Fear of cancer recurrence in an era of personalized medicine

Journal of Clinical Oncology

Volumn 35, Issue 29, 2017, Pages 3275-3278

  Thewes, Belinda ^a   Husson, Olga ^a   Poort, Hanneke ^a   Custers, Jose A E ^a   Butow, Phyllis N ^b   McLachlan, Sue Anne ^c   Prins, Judith B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; FEAR; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALIGNANT NEOPLASM; NOTE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT RESPONSE; ATTITUDE TO HEALTH; CANCER SURVIVOR; DISEASE EXACERBATION; GENETIC PREDISPOSITION; GENETICS; METASTASIS; MOLECULARLY TARGETED THERAPY; MORTALITY; NEOPLASM; PHENOTYPE; PROCEDURES; PSYCHOLOGY; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

BIOMARKERS, TUMOR; CANCER SURVIVORS; DISEASE PROGRESSION; FEAR; GENETIC PREDISPOSITION TO DISEASE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PHENOTYPE; PRECISION MEDICINE; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85032491777     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.72.8212     Document Type: Note

References (55)

1. Ryerson AB, Eheman CR, Altekruse SF, et al: Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 122:1312-1337, 2016
2. International Agency for Research on Cancer: World cancer report 2014. http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014
3. Lebel S, Ozakinci G, Humphris G, et al: From normal response to clinical problem: Definition and clinical features of fear of cancer recurrence. Support Care Cancer 24:3265-3268, 2016
4. Simard S, Thewes B, Humphris G, et al: Fear of cancer recurrence in adult cancer survivors: A systematic review of quantitative studies. J Cancer Surviv 7: 300-322, 2013
5. Herschbach P, Dinkel A: Fear of progression, in Goerling U (ed): Psychooncology, Berlin, Germany, Springer, pp 11-29
6. Lee-Jones C, Humphris G, Dixon R, et al: Fear of cancer recurrence—A literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Psychooncology 6:95-105, 1997
7. Thewes B, Butow P, Bell ML, et al: Fear of cancer recurrence in young women with a history of early-stage breast cancer: A cross-sectional study of prevalence and association with health behaviours. Support Care Cancer 20: 2651-2659, 2012
8. Crist JV, Grunfeld EA: Factors reported to influence fear of recurrence in cancer patients: A systematic review. Psychooncology 22:978-986, 2013
9. Lebel S, Tomei C, Feldstain A, et al: Does fear of cancer recurrence predict cancer survivors’ health care use? Support Care Cancer 21:901-906, 2013
10. Custers JA, Gielissen MF, de Wilt JH, et al: Towards an evidence-based model of fear of cancer recurrence for breast cancer survivors. J Cancer Surviv 11: 41-47, 2017
11. Koch L, Bertram H, Eberle A, et al: Fear of recurrence in long-term breast cancer survivors-still an issue. Results on prevalence, determinants, and the association with quality of life and depression from the cancer survivorship—A multi-regional population-based study. Psychooncology 23: 547-554, 2014
12. Yang Y, Cameron J, Humphris G: The relationship between cancer patient’s fear of recurrence and radiotherapy: A systematic review and meta-analysis. Psychooncol 10.1002/pon.4224 [epub ahead of print on July 15, 2016]
13. Fardell JE, Thewes B, Turner J, et al: Fear of cancer recurrence: A theoretical review and novel cognitive processing formulation. J Cancer Surviv 10:663-673, 2016
14. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
15. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001
16. Blay JY: A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. Cancer Treat Rev 37: 373-384, 2011
17. Artinyan A, Kim J, Soriano P, et al: Metastatic gastrointestinal stromal tumors in the era of imatinib: Improved survival and elimination of socioeconomic survival disparities. Cancer Epidemiol Biomarkers Prev 17:2194-2201, 2008
18. Casali PG: Successes and limitations of targeted cancer therapy in gastrointestinal stromal tumors. Prog Tumor Res 41:51-61, 2014
19. Ravaud A, Motzer RJ, Pandha HS, et al: Adjuvant sunitinib in high-risk renal cell carcinoma after nephrectomy. N Engl J Med 375:2246-2254, 2016
20. Efficace F, Breccia M, Cottone F, et al: Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. Support Care Cancer 24:4887-4894, 2016
21. Phillips KM, Pinilla-Ibarz J, Sotomayor E, et al: Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A controlled comparison. Support Care Cancer 21:1097-1103, 2013
22. Poort H, Meade CD, Knoop H, et al: Adapting an evidence-based intervention to address targeted therapy-related fatigue in chronic myeloid leukemia patients. Cancer Nurs [epub ahead of print on November 8, 2016]
23. Etienne G, Guilhot J, Rea D, et al: Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 35: 298-305, 2017
24. Breccia M, Efficace F, Sica S, et al: Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leuk Res 39:1055-1059, 2015
25. von Mehren M, Randall RL, Benjamin RS, et al: Gastrointestinal stromal tumors, version 2.2014. J Natl Compr Canc Netw 12:853-862, 2014
26. ESMO/European Sarcoma Network Working Group: Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:iii21-iii26, 2014 (suppl 3)
27. Custers JA, Tielen R, Prins JB, et al: Fear of progression in patients with gastrointestinal stromal tumors (GIST): Is extended lifetime related to the Sword of Damocles? Acta Oncol 54:1202-1208, 2015
28. Corless CL, Ballman KV, Antonescu CR, et al: Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: The ACOSOG Z9001 trial. J Clin Oncol 32:1563-1570, 2014
29. Meiser B, Quinn VF, Gleeson M, et al: When knowledge of a heritable gene mutation comes out of the blue: Treatment-focused genetic testing in women newly diagnosed with breast cancer. Eur J Hum Genet 24:1517-1523, 2016
30. Liang R, Meiser B, Smith S, et al: Advanced cancer patients’ attitudes towards, and experiences with, screening for somatic mutations in tumours: A qualitative study. Eur J Cancer Care (Engl) [epub ahead of print on October 11, 2016]
31. Yusuf RA, Rogith D, Hovick SRA, et al: Attitudes toward molecular testing for personalized cancer therapy. Cancer 121:243-250, 2015
32. Gray SW, Hicks-Courant K, Lathan CS, et al: Attitudes of patients with cancer about personalized medicine and somatic genetic testing. J Oncol Pract 8: 329-335, 2, 335, 2012
33. Duric V, Stockler M: Patients’ preferences for adjuvant chemotherapy in early breast cancer: A review of what makes it worthwhile. Lancet Oncol 2: 691-697, 2001
34. Duric VM, Stockler MR, Heritier S, et al: Patients’ preferences for adjuvant chemotherapy in early breast cancer: What makes AC and CMF worthwhile now? Ann Oncol 16:1786-1794, 2005
35. Thomas RK, Baker AC, Debiasi RM, et al: High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347-351, 2007
36. [Erratum: Nat Genet 39:567, 2007]
37. Wood LD, Parsons DW, Jones S, et al: The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113, 2007
38. Luke JJ, Ott PA: PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma. Oncotarget 6:3479-3492, 2015
39. Hodi FS, O’Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
40. Burstein HJ, Krilov L, Aragon-Ching JB, et al: Clinical cancer advances 2017: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 35:1341-1367, 2017
41. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
42. Weber JS, Hodi FS, Wolchok JD, et al: Safety profile of nivolumab mon-otherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol 35: 785-792, 2017
43. Thewes B, Butow P, Zachariae R, et al: Fear of cancer recurrence: A systematic literature review of self-report measures. Psychooncology 21:571-587, 2012
44. Curran D, van Dongen JP, Aaronson NK, et al: Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: Results of EORTC Trial 10801. The European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Co-operative Group (BCCG). Eur J Cancer 34:307-314, 1998
45. Hunter DJ: Uncertainty in the era of precision medicine. N Engl J Med 375: 711-713, 2016
46. Thewes B, Prins JB, Friedlander M: 70-gene signature in early-stage breast cancer. N Engl J Med 375:2199-2201, 2016
47. Butow PN, Bell ML, Smith AB, et al: Conquer fear: Protocol of a randomised controlled trial of a psychological intervention to reduce fear of cancer recurrence. BMC Cancer 13:201, 2013
48. van de Wal MA, Gielissen MF, Servaes P, et al: Study protocol of the SWORD-study: A randomised controlled trial comparing combined online and face-to-face cognitive behaviour therapy versus treatment as usual in managing fear of cancer recurrence. BMC Psychol 3:12, 2015
49. Maheu C, Lebel S, Courbasson C, et al: Protocol of a randomized controlled trial of the fear of recurrence therapy (FORT) intervention for women with breast or gynecological cancer. BMC Cancer 16:291, 2016
50. Lebel S, Maheu C, Lefebvre M, et al: Addressing fear of cancer recurrence among women with cancer: A feasibility and preliminary outcome study. J Cancer Surviv 8:485-496, 2014
51. van de Wal M, Thewes B, Gielissen M, et al: Efficacy of blended cognitive behavior therapy for high fear of recurrence in breast, prostate, and colorectal cancer survivors: The SWORD study, a randomized controlled trial. J Clin Oncol 10.1200/JCO.2016.70.5301 [epub ahead of print on May 4, 2017]
52. Herschbach P, Berg P, Waadt S, et al: Group psychotherapy of dysfunctional fear of progression in patients with chronic arthritis or cancer. Psychother Psychosom 79:31-38, 2010
53. van Helmondt SJ, van der Lee ML, de Vries J: Study protocol of the CAREST-trial: A randomised controlled trial on the (cost-) effectiveness of a CBT-based online self-help training for fear of cancer recurrence in women with cu-ratively treated breast cancer. BMC Cancer 16:527, 2016
54. Smith A, Thewes B, Turner J, et al: Pilot of a theoretically grounded psychologist-delivered intervention for fear of cancer recurrence (Conquer Fear). Psychooncology 24:967-970, 2015
55. Maheu C, Lebel S, Tomei C, et al: Breast and ovarian cancer survivors’ experience of participating in a cognitive-existential group intervention addressing fear of cancer recurrence. Eur J Oncol Nurs 19:433-440, 2015